Retrospective Study
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Dec 15, 2021; 12(12): 2087-2095
Published online Dec 15, 2021. doi: 10.4239/wjd.v12.i12.2087
Efficacy of omarigliptin, once-weekly dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes
Eiji Kawasaki, Yuko Nakano, Takahiro Fukuyama, Aira Uchida, Yoko Sagara, Hidekazu Tamai, Masayuki Tojikubo, Yuji Hiromatsu, Nobuhiko Koga
Eiji Kawasaki, Yuko Nakano, Takahiro Fukuyama, Aira Uchida, Yoko Sagara, Hidekazu Tamai, Masayuki Tojikubo, Yuji Hiromatsu, Nobuhiko Koga, Department of Diabetes and Endocrinology, Shin-Koga Hospital, Kurume 830-8577, Japan
Author contributions: Kawasaki E designed and performed the research and wrote the manuscript; Kawasaki E contributed to the conception, design of the work, analysis, and interpretation of data for the work; Nakano Y contributed to the analysis and interpretation of data for the work; Fukuyama T, Uchida A, Sagara Y, Tamai H, Tojikubo M, Hiromatsu Y, and Koga N contributed to the interpretation of data for the work; All authors have read and approved the final manuscript.
Institutional review board statement: This study’s protocol has been reviewed and approved by the ethics committee of Shin-Koga hospital.
Informed consent statement: To collected the retrospective data patients did not provide their verbal or written informed consent to join the study but were instead allowed to refuse participation according to the Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects and the local Institutional Review Board Approval due to its retrospective nature. As for the continuous glucose monitoring study, all patients provided informed written consent prior to enrollment.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Eiji Kawasaki, MD, PhD, Director, Department of Diabetes and Endocrinology, Shin-Koga Hospital, 120 Tenjin-cho, Kurume 830-8577, Japan. e-kawasaki@tenjinkai.or.jp
Received: February 3, 2021
Peer-review started: February 3, 2021
First decision: August 19, 2021
Revised: September 1, 2021
Accepted: December 8, 2021
Article in press: December 8, 2021
Published online: December 15, 2021
Core Tip

Core Tip: This paper reported on the efficacy of omarigliptin in Japanese patients with type 2 diabetes who had previously received treatment with other glucose-lowering agents. The present study demonstrated that administering omarigliptin as add-on therapy or switching to it from sitagliptin and linagliptin, but not vildagliptin, provides more effective glycemic control. Ultimately, these findings should help decision-making in the actual clinical setting when selecting and using dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.